Polyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and mice

Santhosh Karanth1,2, Vy My Tran3, Balagurunathan Kuberan3,4 and Amnon Schlegel1,2,5,*

SUMMARY

Lipid disorders pose therapeutic challenges. Previously we discovered that mutation of the hepatocyte β-hydroxybutyrate transporter SLC16A6A in zebrafish causes hepatic steatosis during fasting, marked by increased hepatic triacylglycerol, but not cholesterol. This selective diversion of trapped ketogenic carbon atoms is surprising because acetate and acetoacetate can exit mitochondria and can be incorporated into both fatty acids and cholesterol in normal hepatocytes. To elucidate the mechanism of this selective diversion of carbon atoms to fatty acids, we fed wild-type and slc16a6a mutant animals high-protein ketogenic diets. We find that slc16a6a mutants have decreased activity of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr), despite increased Hmgcr protein abundance and relative incorporation of mevalonate into cholesterol. These observations suggest the presence of an endogenous Hmgcr inhibitor. We took a candidate approach to identify such inhibitors. First, we found that mutant livers accumulate multiple polyunsaturated fatty acids (PUFAs) and PUFA-CoAs, and we showed that human HMGCR is inhibited by PUFA-CoAs in vitro. Second, we injected mice with an ethyl ester of the PUFA eicosapentaenoic acid and observed an acute decrease in hepatic Hmgcr activity, without alteration in Hmgcr protein abundance. These results elucidate a mechanism for PUFA-mediated cholesterol lowering through direct inhibition of Hmgcr.

INTRODUCTION

Atherosclerotic cardiovascular disease is the leading cause of death worldwide (Lozano et al., 2012). Elevated serum cholesterol is a causal risk factor for the development and progression of atherosclerosis (Kannel et al., 1964). The most widely used treatment for atherosclerosis is statin drugs, which potently inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and dramatically lower cardiovascular mortality (Baigent et al., 2010). Nevertheless, a substantial fraction of people receiving statin drugs do not tolerate them, with vague muscle aches being the main cause of drug discontinuation (Reinhart and Woods, 2012). Hence, there is considerable interest in identifying alternative strategies for lowering serum cholesterol, including life-style changes, micronutrient supplementation and pharmaceutical development.

A greater understanding of the underlying factors regulating lipid metabolism holds the promise of yielding novel therapies. The zebrafish has numerous technical advantages for modeling human diseases (Lieschke and Currie, 2007), and is emerging as a major resource for studying lipid metabolism (Schlegel, 2012; Sadler et al., 2013). First, the zebrafish utilizes a lipid packaging machinery that is conserved among metazoans to transport neutral lipids from their sites of absorption (intestine and yolk) or synthesis (liver) to peripheral organs. The molecular players involved include apolipoproteins (Babin et al., 1997) and apolipoprotein processing enzymes (Marza et al., 2005; Schlegel and Stainier, 2006). Following release into the circulation, lipoproteins are modified in zebrafish blood by a machinery that is also highly conserved in evolution. For instance, zebrafish carry an ortholog of the human cholesteryl ester transfer protein (CETP) gene. A CETP ortholog is frustratingly absent in commonly used rodent models (Haa and Barter, 1982), rendering the study of atherosclerosis difficult: rodents are inherently resistant to atherosclerosis (Yin et al., 2012), and background manipulations such as targeted deletion of the Apoe or Ldlr genes are required to drive atherosclerosis. Unlike mice and rats, an ortholog of the human CETP gene is retained in zebrafish, causing the circulating lipoprotein particles to resemble human lipoprotein particles in abundance and composition; this conserved lipoprotein metabolism contributes to the susceptibility of zebrafish to atherosclerosis when placed on a high-cholesterol diet (Stoletov et al., 2009). Furthermore, the deposition of sub-intimal cholesterol can be monitored in real time, in live animals (Fang et al., 2011). In addition to their genetic propensity to developing atherosclerosis when placed on high-cholesterol diets, zebrafish develop obesity, hypertriglyceridaemia, hepatic steatosis and characteristic adipocyte gene expression changes when over-fed their normal diet (Oka et al., 2010). These effects can be reversed by caloric restriction.

In a forward genetic screen for zebrafish mutants with lipid storage defects, we discovered that the liver has a dedicated β-hydroxybutyrate transporter whose loss causes nutritionally suppressible hepatic steatosis (Hugo et al., 2012). This transporter normally exports the major ketone bodies produced by the liver under starvation conditions, acetoacetate and β-hydroxybutyrate, which are partially oxidized short-chain fatty acid catabolites of longer-chain fatty acids and certain amino acids. Together, these ketone bodies are the major fuel of fasting, providing energy to the
brain when glucose is depleted (Cahill, 2006). When administered radiolabeled leucine, a ketogenic amino acid, never-fed zebrafish slc16a6a mutant larvae divert the trapped ketogenic carbon atoms into triacylglycerol exclusively (Hugo et al., 2012). This selectivity is unanticipated because carbon atoms from mitochondrial leucine catabolism can be funneled to cytoplasmic cholesterol. Specifically, the acetate and acetoacetate generated from leucine breakdown can exit mitochondria and be used to synthesize both fatty acids and cholesterol (Mathias et al., 1981).

Here we identify a molecular mechanism for this selective diversion of carbon atoms to fatty acyl chains and not to cholesterol that has broad implications for the pharmacological suppression of cholesterol synthesis. We trigger severe hepatic steatosis in slc16a6a mutants by feeding them ketogenic diets, and find that, in addition to triacylglycerol, polyunsaturated fatty acid (PUFA)-CoAs (activated intermediates of neutral and phospholipid synthesis) accumulate in the mutants’ livers. Furthermore, PUFA-CoAs are competitive inhibitors of Hmgcr in vitro, with physiologically plausible kinetic properties. Finally, short-term administration of a high dose of a single PUFA ethyl ester to mice decreases liver Hmgcr activity, without altering Hmgcr protein abundance. Chronic administration of PUFA-CoAs to mice disrupts the maturation of sterol-regulatory element binding proteins (SREPBs), the master transcription factors controlling lipid synthesis, and indirectly lowers expression of several genes encoding enzymes involved in fat and cholesterol production (Worgall et al., 1998; Mater et al., 1999; Xu et al., 1999; Yahagi et al., 1999). Furthermore, chronic PUFA supplementation can ameliorate hepatic steatosis in ob/ob mice through suppressing Srebp1 (Sekiya et al., 2003). Our findings indicate that PUFA-CoAs (specifically) also have a direct inhibitory effect on Hmgcr activity. These findings elucidate a newly identified beneficial role to high dose fish oil supplementation.
they were all increased in the mutant livers (Fig. 2A-C). Furthermore, several saturated and unsaturated fatty acyl species were increased in whole-lipid extracts of mutant livers (Fig. 2D). Cholesteryl esters were lower and free cholesterol was unchanged (Fig. 2E). Recapitulating our measurement of β-hydroxybutyrate in fasted \textit{slc16a6a} mutants (Hugo et al., 2012), total ketone bodies were all increased in the mutant livers from animals on either ketogenic diet (K4 or K12). These results suggest that severely decreased Hmgcr activity might explain why liver cholesterol levels are not increased in steatotic \textit{slc16a6a} mutants.

**Decreased Hmgcr activity in the face of increased protein abundance is observed in statin treatment (Brown et al., 1978).** To understand why \textit{slc16a6a} mutants show increased hepatic accumulation of triacylglycerol only, we assessed the abundance and processing into mature, activated N-terminal fragments of the master transcription factors governing triacylglycerol and cholesterol biosynthesis, Srebf1 and Srebf2, respectively (Jeon and Osborne, 2012). In mutant livers from animals fed either diet, both Srebf proteins showed increased maturation into cleaved N-terminal fragments (Fig. 3A). Wild-type (WT) livers showed appropriate suppression of Srebf2 activation in K12-fed animals. In whole-liver lysates, the degree of Srebf1 processing relative to the total detected was less dramatic than for Srebf2: similar to Srebf1 processing in rat livers, several intermediates of processing and mature fragments of Srebf1 were detected (Owen et al., 2012). In purified nuclei, activated Srebf1 was strikingly increased in \textit{slc16a6a} mutants (Fig. 3A).

Next, we measured the steady-state abundance of Srebf-regulated transcripts encoding crucial enzymes of cholesterol biosynthesis, \textit{de novo} fatty acid synthesis, triacylglycerol production and very-low-density lipoprotein (VLDL) assembly. Mirroring the effect of fasting (Hugo et al., 2012), \textit{slc16a6a} mutants on the K4 diet showed increased expression of several transcripts encoding enzymes of these pathways: \textit{de novo} lipogenesis (\textit{acaca}, \textit{fasl}), triacylglycerol synthesis (\textit{dgat2}) and VLDL assembly (\textit{mtp}) (Fig. 3B). Likewise, the \textit{hmgcr} transcript was induced in \textit{slc16a6a} mutants on the K4 diet. Immunoblot analysis of the rate-limiting enzymes of fatty acid synthesis, acetyl-CoA carboxylase (Acac), and of Hmgcr showed that the K12 diet suppressed Acac and Hmgcr protein levels in WT animals; however, \textit{slc16a6a} mutants showed increased abundance of both proteins on both diets (Fig. 3A). These gene expression and protein abundance results indicated that the increase in triacylglycerol in \textit{slc16a6a} mutant livers might be due, in part, to Acac induction (and of \textit{de novo} lipogenesis, more generally), but the decrease in cholesterol cannot be explained by a simple decrease in Hmgcr protein. Acac serine phosphorylation on Ser80, a post-translational modification catalyzed by AMP-dependent kinase that serves as a feedback control on enzyme activity, was increased in both \textit{slc16a6a} mutant groups (Brownsey et al., 2006). Hmgcr is also phosphorylated by AMP-dependent kinase on the conserved Ser868 residue; however, commercial antibodies fail to detect this site because flanking residues are not sufficiently conserved (supplementary material Fig. S3). Hmgcr phosphorylation is an early event in the feedback inhibition of Hmgcr, exerting a maximal inhibition (30% of control) of this enzyme within 20 minutes of gavage of the product mevalonolactone (Arebalo et al., 1980). Over longer periods of time, Hmgcr phosphorylation seems to be a less significant contributor to alterations in rat cholesterol synthesis than Hmgcr protein abundance (Brown et al., 1979). Because Hmgcr protein was more abundant in both \textit{slc16a6a} mutant groups, we were surprised to observe that, in liver homogenates, Hmgcr activity was 40% lower in \textit{slc16a6a} mutants (Fig. 3C). This reduction in Hmgcr activity was comparable to that seen in WT animals on the K12 diet whose Hmgcr abundance is much lower. These results suggest that severely decreased Hmgcr activity might explain why liver cholesterol levels are not increased in steatotic \textit{slc16a6a} mutants.
tracer incorporation into triacylglycerol and cholesterol. It is important to note that such a labeling approach in higher vertebrates is fraught with technical pitfalls: the mitochondrial pool of acetate can be syphoned into ketone bodies at a rate greater than the cytoplasmic pool can be incorporated into cholesterol, with dose of tracer, duration of labeling and presence of unlabeled acetate greatly influencing the incorporation of label into cholesterol (Dietschy and McGarry, 1974). Fortunately for us, the mitochondrial HMG-CoA synthase (Hmgcs2) responsible for this diversion of acetate into ketone bodies is only present in birds and higher vertebrates (Fig. 4A) (Boukaftane et al., 1994; Leblanc and Ballantyne, 2000). Indeed, the absence of Hmgcs2 in zebrafish allowed us to perform leucine labeling in fasting to obtain unambiguous evidence that Slc16a6a is a hepatic ketone body transporter (Hugo et al., 2012).

Consistent with the presence of a specific block at the level of Hmgcr, acetate showed greater incorporation into triacylglycerol in mutant livers, whereas mevalonate showed enhanced incorporation into cholesterol (Fig. 4A–C). This latter finding also indicates that the roughly 30 enzymatic steps following Hmgcr in catalyzing cholesterol synthesis are not defective in mutant livers (Brown et al., 1978). To address whether Hmgcr inhibition could be achieved outside our ketogenic dietary model, we subjected animals that were maintained on conventional diets to a fast and assessed the incorporation of radiolabeled acetate into cholesterol and triacylglycerol. Consistent with our results in ketogenic-diet-fed animals, slc16a6a mutants showed blunted incorporation of acetate into cholesterol when fasted (Fig. 4D). This result validated our ketogenic dietary paradigm and strongly suggests that Hmgcr activity is inhibited in slc16a6a mutant livers even though the protein is more abundant.

**PUFA-CoAs inhibit Hmgcr**

To identify an endogenous inhibitor of Hmgcr, we took a candidate approach, focusing on ketone bodies first. We chose these...
metabolites because CoA thioesters of ketone bodies inhibit carboxyl anhydrases in vitro (Parkkila et al., 2012) and β-hydroxybutyrate inhibits histone deacetylases in vivo (Shimazu et al., 2013). These metabolites also share a potential pharmacophore moiety with statin inhibitors of Hmgcr (Fig. 5A). Neither β-hydroxybutyryl-CoA nor acetocetyl-CoA, however, inhibited human HMGCR in vitro with a physiologically plausible potency: the inhibition constant \( K_i \) values for these metabolites were 10- and 14-times greater than the Michaelis-Menten constant \( K_m \) for HMG-CoA, respectively (Fig. 5B). This lack of inhibition also comports with our observation that ketone bodies do not accumulate in \( s l c 16 a 6 a \) livers: the carbon atoms are rerouted to other metabolites (Fig. 2F,G).

Interestingly, mice have lower serum cholesterol, hepatic cholesterol and hepatic Hmgcr activity when fed a defined diet with very high levels of a single PUFA (Du et al., 2003). In addition, intrahepatic fatty acyl-CoAs increase during fasting (Tubbs and Garland, 1964), and Hmgcr is inhibited by select fatty acyl-CoAs in vitro (Kuroda and Endo, 1976; Faas et al., 1977; Faas et al., 1978; Lehrer et al., 1981; Roitelman and Shechter, 1989). Detailed kinetic analyses, however, were not reported in some of these studies and, for short-chain fatty acyl-CoAs, the kinetic parameters do not support physiological inhibition. Fourth, total free fatty acids were increased in \( s l c 16 a 6 a \) mutant livers (Fig. 2D,E). These observations led to the hypothesis that \( s l c 16 a 6 a \) mutants accumulate fatty acyl chains and their CoA thioesters are inhibitors of Hmgcr.

We found that six FA-CoAs could be reliably detected in wild-type and \( s l c 16 a 6 a \) mutant livers at the conclusion of the feeding study. Palmitoyl-CoA (PA-CoA) was the most abundant species and was increased in both \( s l c 16 a 6 a \) groups. Linolenyl-CoA (LA-CoA) showed a similar increase in \( s l c 16 a 6 a \) groups. The PUFA-CoAs eicosapentaenyl-CoA (EPA-CoA) and docosahexaenyl-CoA (DHA-CoA) were not increased in the mutants (Fig. 6A); however, the intermediates of their synthesis, stearidonyl-CoA (SA-CoA) and eicosatetraenyl-CoA (ETA), were increased two- to three-fold, although the lack of commercial standards precluded absolute quantification of these two species.

Because several fatty acyl-CoA species were more abundant in \( s l c 16 a 6 a \) livers, we tested whether they were inhibitors of human HMGCR in Michaelis-Menten analysis (Fig. 6B). We included EPA-CoA and DHA-CoA in these studies because they are the active components of pharmaceutical fish oils. We found that LA-CoA, EPA-CoA and DHA-CoA are physiologically plausible competitive HMGCR inhibitors \( K_i \); for each was less than the \( K_m \) for HMG-CoA). Unsaturation seemed to be crucial to this inhibitory activity: \( K_i \) of fully saturated PA-CoA is more than double the \( K_m \) for HMG-CoA, yet its abundance is increased in \( s l c 16 a 6 a \) mutant livers (Fig. 6A).

Although these \( i n \ v i t r o \) findings were promising, the \( K_i \) values for PUFA-CoAs are, nevertheless, higher than those of statin drugs. This suggests that inhibition of Hmgcr by PUFA-CoAs in \( i n \ v i v o \) requires achieving relatively high intracellular concentrations. We directly tested whether acute administration of PUFAs might decrease Hmgcr activity \( i n \ v i v o \) by injecting mice intraperitoneally with EPA-ethyl ester (EPA-EE), a pharmacological form of an n-3 PUFA that is limiting in mammals (Huang et al., 1991). There was a decrease in hepatic Hmgcr activity observed with the higher dose of EPA-EE (Fig. 7A). Parallel injection of a statin inhibitor of Hmgcr caused a dose-dependent decrease in activity, as well (supplementary material Fig. S4A). Importantly, Hmgcr protein abundance was not altered by this short course of either EPA-EE or statin treatment (Fig. 7B,C and supplementary material Fig. S4B).

**DISCUSSION**

Treatment of pandemic atherosclerosis poses a major therapeutic challenge in that the most effective agents – statin HMGCR
inhibitors – are not uniformly tolerated. Furthermore, large adequately powered trials of statins in combination with a fibrate, niacin or inhibitors of cholesterol absorption have not demonstrated added benefit, despite enhanced lipid lowering (Baigent et al., 2011; Ginsberg et al., 2010; Boden et al., 2011). Furthermore, unanticipated side effects such as renal impairment

Fig. 4. In vivo inhibition of Hmgcr in slc16a6a mutant livers. (A) Ketogenesis involves a series of reactions mostly in the mitochondria of hepatocytes, where fatty-acid-derived and select ketogenic-amino-acid-derived carbon atoms are oxidized to acetoacetate. In this scheme, catabolism of acetate (from fatty acids) and the branched-chain amino acid leucine are shown in detail. The terminal product of this pathway is acetoacetate, which can undergo spontaneous decarboxylation to acetone, or be partially reduced to β-hydroxybutyrate. When ketone body export is prevented by mutation of zebrafish slc16a6a, the trapped ketone body carbon atoms are diverted to de novo lipogenesis, but not to cholesterol. Cholesterol biosynthesis is prevented by inhibition of Hmgcr by the PUFA-CoAs that accumulate during de novo lipogenesis. The 3H-marked isotopes injected intraperitoneally were used to address whether there was a block in Hmgcr activity in vivo. Note that Hmgcs2 is lacking in zebrafish, eliminating this pathway of acetate consumption. (B,C) Wild-type (WT) and slc16a6a mutant (MUT) animals fed ketogenic diets for 45 days were injected intraperitoneally with 3H-labeled acetate and 3H-labeled mevalonate, and the incorporation of radiotracers into cholesterol and triacylglycerol was measured. Results are reported as disintegrations per minute per nanomole of the indicated lipid. Groups with different letters are statistically different, P ≤0.05, Duncan’s multiple range test. All data mean ± s.e.m. (n=3 per group). (D) Incorporation of radiolabeled acetate into cholesterol and triacylglycerol in WT and MUT animals subjected to a 10-day fast. Groups with different letters are statistically different, P ≤0.001, two-sided Student’s t-test. All data mean ± s.d. (n=5 per group).
Bonds et al., 2012), and muscle and liver injury are observed in these trials (HPS2-THRIVE Collaborative Group, 2013).

Although our initial goal in this work was to address why blocking ketone body secretion triggers a triacylglycerol-only steatosis, we have uncovered a novel therapeutic possibility for overcoming the therapeutic shortcoming of statin adjuvants. By developing high-protein ketogenic diets, we were able to create experimental conditions for demonstrating that, when export of ketone bodies from the liver is impaired, PUFA-CoAs accumulate. Because zebrafish can synthesize PUFAs from plant-derived dietary unsaturated fatty acids (UFAs) (Hastings et al., 2001; Tocher et al., 2001), this model organism provided a unique opportunity to investigate the effect of PUFAs on cholesterol synthesis in a vertebrate. Our findings in this organism indicate that liver-trapped carbon atoms can accumulate into PUFAs that are not only incorporated into triacylglycerol, but their CoA thioesters inhibit cholesterol synthesis. Metabolite-based modulation of Hmgcr activity seems to occur in parallel to known direct regulators of this enzyme, such as phosphorylation or proteasome-mediated degradation (Burg and Espenshade, 2011).

Chronic PUFA supplementation also impairs Srebp1c maturation in mice, and thereby limits de novo lipogenesis. PUFA-mediated Srebp1c inhibition seems to involve two mechanisms. The first involves the altered biophysical properties of endoplasmic reticulum membranes when PUFAs are incorporated in phospholipid side chains: such incorporation into phospholipids suppresses the unfolded protein response, a potent trigger of Srebp1c activation (Ariyama et al., 2010; Lagace and Ridgway, 2013). The second mechanism of PUFA-mediated Srebp1c inhibition involves antagonism of Liver X receptor (Lxr)-driven induction of Srebp1c expression (Yoshikawa et al., 2002; Howell et al., 2009). These mechanisms governing Srebp1 regulation act in parallel to one another, and with still other known pathways. For instance, chronic fish oil supplementation triggers selective repression of mouse nuclear Srebp1c accumulation, and accelerates Srebp1c proteosomal degradation; interestingly, PUFA supplements seem to have no effect on Srebp2 (Botolin et al., 2006). Zebrafish seem to have only a single srebf1 transcript variant, unlike higher vertebrates, in whom two major variants encoding Srebp1a and Srebp1c are present. Zebrafish have a single Lxr ortholog, making this model organism potentially useful for examining Srebp regulation by Lxr in the future (Bertrand et al., 2007; Archer et al., 2008).

Thus, our in vitro studies with purified human HMGCR catalytic domains indicate that acute HMGCR inhibition by their CoA thioesters is another mode whereby PUFAs regulate lipid metabolism. PUFA-CoAs seem to be unique in their ability to inhibit HMGCR, in that fully saturated PA-CoA had physiologically implausible kinetic parameters. Likewise, the short course of EPA-EE decreased Hmgcr activity in mouse liver homogenates, without altering Hmgcr abundance. Thus, contrary to initial reports (Taketa and Pogell, 1966; Zahler et al., 1968) but consistent with later observations (Powell et al., 1981; Constantinides and Steim, 1985), fatty acyl-CoAs are not merely detergents that denature a broad range of enzymes.

Although feeding of high-DHA diets lowers serum cholesterol, reduces hepatic cholesterol content and lowers hepatic Hmgcr activity in mice (Du et al., 2003), conventional fish oil doses (rich in DHA and EPA) do not lower serum cholesterol in humans (Eslick et al., 2009). This contrasts with the low total cholesterol seen in native Greenlanders (Bang et al., 1971), a population that consumes diets very high in n-3 fatty acids and has a very low prevalence of coronary atherosclerosis (Bang et al., 1980). Moreover, diets high in PUFAs are associated with low levels of serum cholesterol and triacylglycerol in many populations, and with low incidence of atherosclerosis (Keys et al., 1966). Promisingly, high-dose supplementation with fish oils rich in DHA has a fairly potent serum-cholesterol-lowering effect even in the setting of statin-treated dyslipidemia, particularly if the total cholesterol remained high following statin initiation (Meyer et al., 2007). Likewise, trials
Fig. 6. PUFA-CoAs are competitive inhibitors of HMGCR. (A) The synthetic pathway of n-3 polyunsaturated fatty acids is shown. From plant-derived α-linolenic acid (C18:3), a series of desaturation and elongation reactions generate two species that are the pharmacologically active species in fish oil preparations: eicosapentaenoic acid (C20:5) and docosahexaenoic acid (C22:6). The Δ6-desaturase that catalyzes the conversion of α-linolenic acid to stearidonic acid (C18:4) is strongly expressed in fish species, but not in higher vertebrates. (B) After 45 days on ketogenic diets (K4 or K12), livers were harvested from wild-type (WT) and slc16a6a mutant (MUT) livers, and fatty-acyl CoAs were analyzed. Abundance of individual species is normalized to protein mass (left). For stearidonyl-CoA (SA-CoA) and eicosatetraenyl-CoA (ETA-CoA) (right), commercial standards are not available, and results are reported as relative abundance (chromatogram area/mg protein). Groups with different letters are statistically different, $P \leq 0.05$, Tukey’s HSD. Data are mean ± s.e.m. ($n = 3$ per group). PA, palmitoyl; LA, linolenyl; EPA, eicosapentaenoyl; DHA, docosahexaenoyl; SA, stearidonyl; ETA, eicosatetraenoyl. ND, not detected. (C) Michaelis-Menten analysis of human HMGCR in the presence of the indicated inhibitors.
of high-dose EPA report a similar cholesterol- and triacylglycerol-reducing effect, even when EPA is combined with a statin (Bays et al., 2011; Ballantyne et al., 2012). Crucially, a lower dose of fish oil supplementation does not confer cardiovascular protection (Roncaglioni et al., 2013).

In addition to these dose considerations, the formulation of fish oils affects serum cholesterol parameters. Conventional fish oil preparations (ethyl esters of PUFA mixtures) cause a striking increase in serum LDL cholesterol, often in proportion to the robust serum triacylglycerol lowering effect (Harris et al., 1997; Pownall et al., 1999). These effects seem to be related to the amount of DHA-EE relative to EPA-EE in the n-3 PUFA-EE formulations studied (Jacobson et al., 2012a), although this hypothesis has been challenged (Baum, 2012; Jacobson et al., 2012b). Newer formulations of PUFAs with greater oral bioavailability than PUFA-EEs have been prepared, and they seem to not raise LDL cholesterol (Maki et al., 2013). We found that both DHA-CoA and EPA-CoA inhibited human HMGCR in vitro with kinetic parameters consistent with in vivo relevance. Because the weight of clinical evidence points to EPA-EE as having LDL-cholesterol-lowering properties, we chose to administer this single formulation of fish oils affects serum cholesterol parameters, and we have prepared effective formulations of EPA-EE that are more bioavailable.

In summary, we have presented biochemical, physiological and pharmacological evidence that Hmgcr is inhibited by PUFA-CoAs. Our findings provide a mechanistic basis for the long-standing epidemiological observations that consumption of PUFA-rich diets is associated with low serum cholesterol and lower incidence of atherosclerotic cardiovascular disease. They also support developing and testing new formulations of PUFA supplements for lowering cholesterol.

MATERIALS AND METHODS

Experimental animals

These studies were approved by the University of Utah Institutional Animal Care and Use Committee and the Radiation Safety Committee. Zebrafish work was performed in the laboratory of A.S.; mouse experiments were performed by the laboratory of Donald A. McClain.

Zebrafish

The red moon<sup>osf</sup> null allele of slc16a6a was as we reported previously (Hugo et al., 2012). It is carried on a WIK background, and the WT strain used as a control in all experiments is WIK.

Diets

Two isoproteic and isocaloric diets differing in lipid content were formulated and prepared as explained previously (Karanth et al., 2011; Ballantyne et al., 2012). Crucially, a lower dose of fish oil supplementation does not confer cardiovascular protection (Roncaglioni et al., 2013).

Experimental animals

Morphometric analysis and body composition

During the dietary study, animal mass was measured weekly. At the conclusion of the dietary study, animal length and mass were measured. Length is defined as the distance between the tip of the snout and the caudal peduncle, and was recorded using a Vernier caliper. The composition of fish samples was analyzed at the Hagerman Fish Culture Experimental Station, University of Idaho, following the Association of Official Analytical Chemists standards (Helrich, 1990). Ten fish per group were analyzed.

Light and electron microscopy

Histological analysis was performed at AML Laboratories and transmission electron microscopy was performed at the University of Utah Electron Microscopy Facility, exactly as we described previously (Hugo et al., 2012).
RNA isolation, cDNA synthesis and gene expression profiling
Total RNA was isolated from liver of zebrafish using the standard TRIzol method (Invitrogen, Carlsbad, CA). mRNA in 2 mg of total RNA was converted to cDNA using oligo(dT) primer and random hexamers according to the manufacturer’s instructions for the Clontech (Takara Biotech, Mountain View, CA). The primers for all the transcripts that we measured were described previously (Hugo et al., 2012). The target sequence for each gene was quantified to generate a standard curve of known copy number. Amplification of cDNA samples and DNA standards was carried out according to the manufacturer’s instructions. For thermal cycling and fluorescence detection, an Agilent Technologies Stratagene MX 3000P machine was used.

Immunoblotting
Livers were sonicated in 400 μl of 50 mM Tris (pH 8.0), 150 mM NaCl, 1.0% IGEPAL CA-630, 0.25% sodium deoxycholate, 0.1% SDS and 1 mM EDTA supplemented with protease and phosphatase inhibitor cocktails (Roche Complete MINI and PhosSTOP). Twenty μg of protein (concentration determined with a BCA kit, Thermo) from each lysate was separated by SDS-PAGE, transferred to nitrocellulose membranes and detected with commercially available antibodies: Acaca IgGs were from Cell Signaling (3662, rabbit), Hmgcr IgGs were from Santacruz (H-300, rabbit), Srebf1 IgGs were from Active Motif (clone 2A4, mouse), Srebf2 IgGs were from Novus Biologicals (NBPI-71880, rabbit) and β-tubulin was from Abcam (ab6046, rabbit). ImageJ was used to quantify the relative density of antibodies: Acaca IgGs were from Cell Signaling (3662, rabbit), Hmgcr IgGs were from Santacruz (H-300, rabbit), Srebf1 IgGs were from Active Motif (clone 2A4, mouse), Srebf2 IgGs were from Novus Biologicals (NBPI-71880, rabbit) and β-tubulin was from Abcam (ab6046, rabbit). ImageJ was used to quantify the relative density of

Blood chemistry
Blood glucose levels were measured using a glucose meter (Contour, Bayer). Total lipids were extracted from serum, liver and whole body following the Folch method as described (Iverson et al., 2001). Total cholesterol, cholesterol ester, triglyceride and free fatty acids were resolved using thin layer chromatography (TLC) exactly as we described previously (Schlegel and Stainier, 2006). The abundance of each lipid class was quantified using a standard charring and desiccation protocol described (Minkler et al., 2008). Livers were homogenized in acetonitrile/isopropanol (3 + 1, v/v), and extracted was resolved lipid species. The cholesterol (free and esterified) and triacylglycerol fractions were individually scraped off and put in scintillation vials. Four ml of scintillation fluid was added to the vials and vortexed vigorously. Vials were then placed in the scintillation counter to measure disintegrations. In parallel, 50 μl of the lipid extract was resolved on TLC plates, and abundance was quantified with copper impregnation and charring. For the fasting radiotracer study, 4-month-old homozygous slc16a6a mutant and homozygous WT animals reared on the facility diet were fasted for 10 days, and then injected intraperitoneally with 5 μl of 3H-acetate [1.3×10^6 counts per minute (CPM)] or 3H-mevalonolactone (0.8×10^6 CPM) at 0:00 pm (Kinkel et al., 2010). Twelve hours later, fish were euthanized and dissected. Total lipid from the livers was extracted and dissolved in 200 μl of chloroform, 50 μl of which was loaded onto the TLC plates. After the TLC plates were developed, the plates were placed in a chamber saturated with iodide vapor to visualize resolved lipid species. The cholesterol (free and esterified) and triacylglycerol fractions were individually scraped off and put in scintillation vials. Four ml of scintillation fluid was added to the vials and vortexed vigorously. Vials were then placed in the scintillation counter to measure disintegrations. In parallel, 50 μl of the lipid extract was resolved on TLC plates, and abundance was quantified with copper impregnation and charring. For the fasting radiotracer study, 4-month-old homozygous slc16a6a mutant and homozygous WT animals reared on the facility diet were fasted for 10 days, and then injected intraperitoneally with 5 μl of 3H-acetate (1.3×10^6 CPM). The following morning, livers were harvested 1 hour after a second injection of EPA-EE or vehicle, and subjected to lipid extraction. TLC was performed in duplicate, with half of each sample run for the purpose of scrapping the plates and performing scintillation counting on individual bands, and the other half run on a plate that was subsequently charred for quantitative of lipid species mass.

Fatty acyl profiling
Fatty acid methyl esters were prepared as described in detail (Li and Watkins, 2001), separated by gas chromatography and analyzed by mass spectrometry at the University of Utah Metabolomics Core Facility. Analysis was performed with a Waters GCT Premier mass spectrometer fitted with an Agilent 6890 gas chromatograph on a 30 m Phenomenex ZB5MSi column with a 5 m long guard column.

Fatty acyl-CoA profiling
Fatty acyl-CoAs were extracted from pooled livers (n=3-5) by following the protocol described (Minkler et al., 2008). Livers were homogenized in acetonitrile/isopropanol (3 + 1, v + v), and centrifuged after adding 0.1 M KH₂PO₄. The supernatant was
filtered through a preconditioned 2-(2-pyridyl) ethyl-functionalized silica gel SPE column (Sigma-Aldrich # 54127-U). The column was washed with 1 mL of acetonitrile/isopropanol/water/acetic acid (9 + 3 + 4 + 4, v + v + v + v) and the fatty acyl-CoAs were eluted with 0.5 mL of methanol/250 mM ammonium formate (4 + 1, v + v).

The elutant was analyzed using a capillary C18-HPLC column (0.3 × 100 mm) coupled to an electrospray ionization time-of-flight mass spectrometer (MS) (Bruker Daltonics, USA). The samples were eluted from the capillary C18 column with a linear gradient of 15-90% acetonitrile containing 0.05% dibutylamine at a flow rate of 5 μL/minute for 30 minutes. The MS was acquired in the negative ion mode at the following conditions: cone gas flow rate at 50 L/hour, nozzle temperature at 130°C, drying gas (N2) flow rate at 450 L/hour, spray tip potential at 2.3 kV and nozzle potential at 35 V.

Mouse studies
Six-week-old male C57BL/6 mice were injected intraperitoneally with pravastatin or EPA-EE at 4:00 pm on the day prior to analysis and at 8:00 am on the day of analysis (n=3 mice per dose). The vehicle (control) was DMSO and the total volume delivered was 0.4 mL. Livers were harvested and whole-liver homogenate was used to measure the Hmgcr activity 1 hour after the second injection, as described above for zebrafish livers.

Statistics
Microsoft Excel 2010, Sigmaplot 12.3 and IBM-SPSS 20.0 were used to measure the Hmgcr activity 1 hour after the second injection, 0.4 mL. Livers were harvested and whole-liver homogenate was used to measure the Hmgcr activity 1 hour after the second injection, of 15-90% acetonitrile containing 0.05% dibutylamine at a flow rate of 5 μL/minute for 30 minutes. The MS was acquired in the negative ion mode at the following conditions: cone gas flow rate at 50 L/hour, nozzle temperature at 130°C, drying gas (N2) flow rate at 450 L/hour, spray tip potential at 2.3 kV and nozzle potential at 35 V.

Disease Models & Mechanisms - DMM

PUFA-CoAs inhibit HMGCR

Ariyama, H., Kono, N., Matsuda, S., Inoue, T. and Araoi, H., (2010). Decrease in membrane phospholipid unsaturation induces unfolded protein response. J. Biol. Chem. 285, 22027-22035.

Babin, P. J., Thisse, C., Durliait, M., Andre, M., Akimenko, M. A. and Thisse, B. (1997). Both apolipoprotein E and A-1 genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development. Proc. Natl. Acad. Sci. USA 94, 8622-8627.

Baigent, C., Blackwell, L., Emberson, J., Holland, L. E., Reith, C., Bhala, N., Peto, R., Barnes, E. H., Keelch, A., Simas, J. et al.; Cholesterol Treatment Trials (CTT) Collaboration (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 27,000 participants in 26 randomised trials. Lancet 367, 1670-1681.

Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J. et al.; SHARP Investigators (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181-2192.

Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaachsen, J. L., Brackeen, R. A. and Soni, P. N. (2012). Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am. J. Cardiol. 110, 984-992.

Bang, H. O., Dyerberg, J. and Nielsen, A. B. (1971). Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet 297, 1143-1146.

Bang, H. O., Dyerberg, J. and Sinclair, H. M. (1980). The composition of the Eskimo food in north western Greenland. Am. J. Clin. Nutr. 33, 2657-2661.

Baum, S. J. (2012). EPA and DHA: distinct yet essential n-3 fatty acids. J. Clin. Lipidol. 6, author reply 477-479.

Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaachsen, J. L., Brackeen, R. A. and Soni, P. N. (2011). Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] trial). Am. J. Cardiol. 108, 682-690.

Bertrand, S., Thisse, B., Tavares, R., Sachs, L., Chaumot, A., Bardet, P.-L., Escrivà, H., Dufraisse, M., Marchand, O., Safi, R. et al. (2007). Unexpected novel relational links uncovered by extensive developmental profiling of nuclear receptor expression. PLoS Genet. 3, e188.

Bischoff, K. M. and Rodwell, V. W. (1996). 3-Hydroxy-3-methylglutaryl-coenzyme A reductase from Haloferax volcanii: purification, characterization, and expression in Escherichia coli. J. Bacteriol. 178, 19-23.

Bitman, J. and Wood, D. L. (1982). An improved copper reagent for quantitative densitometric thin-layer chromatography of lipids. J. Liq. Chromatogr. 5, 1153-1162.

Boden, W. E., Probstfield, J. L., Anderson, T., Chaitman, B. R., Desvignes-Nickens, P., Koprowicz, K., McBride, R., Yeo, K., Weintraub, W.; AIM-HIGH Investigators (2011). Nicin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267.

Bonds, D. E., Craven, T. E., Buse, J., Crouse, J. R., Cuddihy, R., Elam, M., Ginsberg, N. H., Kirchner, K., Marcovina, S., Mychaleckyj, J. C. et al. (2012). Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia 55, 1641-1650.

Botolin, D., Wang, Y., Christian, B. and Jumper, D. B. (2006). Docosahexaeanoic acid (22:6n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 265 proteasome-dependent pathways. J. Lipid Res. 47, 181-192.

Boukaftane, Y., Duncan, A., Wang, S., Labuda, D., Robert, M.-F., Sarrazin, J., Schappert, K. and Mitchell, G. A. (1994). Human mitochondrial HMG CoA synthase: liver cDNA and partial genomic cloning, chromosome mapping to 1p12-p13, and possible role in vertebrate evolution. Genomics 23, 552-559.

Brown, M. S., Faust, J. R., Goldenstein, J. L., Kaneko, I. and Endo, A. (1978). Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-2368), a competitive inhibitor of the reductase. J. Biol. Chem. 253, 1121-1128.

Brown, M. S., Goldenstein, J. L. and Dietschy, J. M. (1979). Active and inactive forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the liver of the rat. Comparison with the rate of cholesterol synthesis in different physiological states. J. Biol. Chem. 254, 5144-5149.

Brownswey, R. W., Boone, A. N., Elliott, J. J., Kulpa, J. E. and Lee, W. M. (2006). Regulation of acetyl-CoA carboxylase. Biochem. Soc. Trans. 34, 223-227.

Burg, J. S. and Espenshade, P. J. (2011). Regulation of HMGC-CoA reductase in mammals and yeast. Prog. Lipid Res. 50, 403-410.

Cahill, G. F., Jr (2006). Fuel metabolism in starvation. Annu. Rev. Nutr. 26, 1-22.

Constantinides, P. P. and Stein, J. M. (1985). Physical properties of fatty acyl-CoA. Critical micelle concentrations and micellar size and shape. J. Biol. Chem. 260, 7573-7580.
Disease Models & Mechanisms

Erickson, Ginsberg, Jeon, Dietschy, Faas, Hugo, Jacobson

Comp. Biochem. Physiol. measuring cholesterol synthesis in liver. Biochim. Biophys. Acta 487, 277-286.

Erickson, F. H., Carter, W. J. and Wynn, J. O. (1977). Unfastened fatty acyl-CoA inhibition of cholesterol synthesis in vivo. Biochim. Biophys. Acta 1279-1291.

Engl. J. Med. specified muscle and liver outcomes, and reasons for stopping study treatment.

Friedewald, W. H. N. (2010). Effects of combination lipid therapy in type 2 diabetes mellitus. J. Lipid Res. 36, 360-368.

Gerstein, K., Pani, S. R., Rogers, D. H. and Rudney, H. (1981). Modulation of rat liver 3-hydroxy-3-methylglutaryl coenzyme A reductase by lipid inhibitors, substrates, and cytosolic factors. J. Biol. Chem. 256, 5612-5619.

Lee, Y. and Watkins, B. A. (2001). Analysis of fatty acids in food lipids. In Current Protocols in Food Analytical Chemistry. John Wiley & Sons, Inc.

Lieschke, G. J. and Currie, P. D. (2007). Animal models of human disease: zebrafish swim into view. Nat. Rev. Genet. 8, 353-367.

Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y. et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128.

Maki, K. C., Orloff, D. G., Nicholls, S. J., Dunbar, R. L., Roth, E. M., Curcio, D., Johnson, J., Kling, D. and Davidson, M. H. (2013). A highly bioavailable omega-3 fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT Trial). Clin. Ther. 35, 1400-1411.

Marza, E., Barthe, C., Andre, M., Villeneuve, L., Helou, C. and Babin, P. J. (2005). Developmental expression and nutritional regulation of a zebrafish gene homologous to mammalian microsomal triglyceride transfer protein large subunit. Dev. Dyn. 232, 506-518.

Mater, M. K., Thelen, A. P., Pan, D. A. and Jump, D. B. (1999). Sterol response element-binding protein 1c (SREBP-1c) is involved in the polysaturated fatty acid suppression of hepatic S14 gene transcription. J. Biol. Chem. 274, 32725-32722.

Mathias, M. M., Sullivan, A. C. and Hamilton, J. G. (1981). Fatty acid and cholesterol synthesis from specifically labeled leucine by isolated rat hepatocytes. Lipids 16, 739-743.

Meyer, B. J., Hammersvold, T., Rusan, A. C. and Hove, P. R. (2007). Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidemic subjects. Lipids 42, 109-115.

Minkler, P. E., Kerner, J., Ingalls, S. T. and Hoppel, C. L. (2008). Novel isolation procedure for short-, medium-, and long-chain acyl-coenzyme A esters from tissue. Anal. Chem. 80, 275-276.

National Research Council (1993). Nutrition Requirements of Fish. Washington, DC: National Academic Press.

Oka, C., Kishimura, Y., Zang, L., Hirano, M., Shimada, Y., Wang, Z., Umemoto, N., Kuroyanagi, J., Nishimura, N. and Tanaka, T. (2010). Diet-induced obesity in zebrafish shares common pathophysiological pathways with mammalian obesity. BMC Physiol. 10, 21.

Owen, J. L., Zhang, Y., Bae, S.-H., Farooqui, M. S., Liang, G., Hammer, R. E., Goldstein, J. L. and Brown, M. S. (2012). Inhibition of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6 kinase. Proc. Natl. Acad. Sci. USA 109, 16184-16189.

Parkkila, S., Vullo, D., Maresca, A., Carta, F., Scozzafava, A. and Supuran, C. T. (2012). Serendipitous fragment-based drug discovery: ketogenic diet metabolites and statins effectively inhibit several carbonic anhydrases. Chem. Commun. 48, 3551-3553.

Powell, G. L., Grothusen, J. R., Zimmerman, J. K., Evans, C. A. and Fish, W. W. (1981). A re-examination of some properties of fatty acyl-CoA micelles. J. Biol. Chem. 256, 12470-12477.

Pownall, H., J., Brauchli, D., Kiliç, C., Osmundsen, K., Pao, Q., Payton-Ross, C., Gotto, A. M., Jr. and Ballantyne, C. M. (1999). Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 143, 285-290.

Reinhart, K. M. and Woods, J. A. (2012). Strategies to preserve the use of statins in patients with previous muscular adverse effects. Am. J. Health Syst. Pharm. 69, 291-300.

Roitelman, J. and Shechter, I. (1989). Studies on the catalytic site of rat liver HMGC-CoA reductase: interaction with CoA-thioesters and inactivation by iodoacetamide. J. Lipid Res. 30, 97-107.
PUFA-CoAs inhibit HMGCR

Rombouts, I., Lamberts, L., Celus, I., Lagrain, B., Brijs, K. and Delcour, J. A. (2009). Wheat gluten amino acid composition analysis by high-performance anion-exchange chromatography with integrated pulsed amperometric detection. J. Chromatogr. A 1216, 5557-5562.

Roncaglioni, M. C., Tombesi, M., Avanzini, F., Barlera, S., Caimi, V., Longoni, P., Marzona, I., Milani, V., Silletta, M. G., Tognoni, G. et al.; Risk and Prevention Study Collaborative Group (2013). n-3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 368, 1800-1808.

Ruíz, J. I. and Ochoa, B. (1997). Quantification in the subnanomolar range of phospholipids and neutral lipids by monodimensional thin-layer chromatography and image analysis. J. Lipid Res. 38, 1482-1489.

Sadler, K. C., Rawls, J. F. and Farber, S. A. (2013). Getting the inside tract: new frontiers in zebrafish digestive system biology. Zebrafish 10, 129-131.

Schlegel, A. (2012). Studying non-alcoholic fatty liver disease with zebrafish: a confluence of optics, genetics, and physiology. Cell. Mol. Life Sci. 69, 3953-3961.

Schlegel, A. and Stainier, D. Y. (2006). Microsomal triglyceride transfer protein is required for yolk lipid utilization and absorption of dietary lipids in zebrafish larvae. Biochemistry 45, 15179-15187.

Sekiya, M., Yahagi, N., Matsuzaka, T., Najima, Y., Nakakuki, M., Nagai, R., Ishibashi, S., Osuga, J., Yamada, N. and Shimano, H. (2003). Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 38, 1529-1539.

Shimazu, T., Hirschy, M. D., Newman, J. H. W., Shimizu, K., M. Le Moan, N., Gruber, C. A., Lim, H., Saunders, L. R., Stevens, R. D. et al. (2013). Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339, 211-214.

Stolov, K., Fang, L., Choi, S.-H., Hartvigsen, K., Hansen, L. F., Hall, C., Pattison, J., Juliano, J., Miller, E. R., Almazan, F. et al. (2009). Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish. Circ. Res. 104, 952-960.

Taketa, K. and Pogell, B. M. (1966). The effect of palmitoyl coenzyme A on glucose 6-phosphate dehydrogenase and other enzymes. J. Biol. Chem. 241, 720-726.

Tocher, D. R., Agaba, M., Hastings, N., Bell, J. G., Dick, J. R. and Teale, A. J. (2001). Nutritional regulation of hepatocyte fatty acid desaturation and polyunsaturated fatty acid composition in zebrafish (Danio rerio) and tilapia (Oreochromis niloticus). Fish Physiol. Biochem. 24, 309-320.

Tubbs, P. K. and Garland, P. B. (1964). Variations in tissue contents of coenzyme A thioesters and possible metabolic implications. Biochem. J. 93, 550-557.

Wilson, J. M., Bunte, R. M. and Carty, A. J. (2009). Evaluation of rapid cooling and tricaine methanesulfonate (MS222) as methods of euthanasia in zebrafish (Danio rerio). J. Am. Assoc. Lab. Anim. Sci. 48, 785-789.

Worgall, T. S., Sturley, S. L., See, T., Osborne, T. F. and Deckelbaum, R. J. (1998). Polyunsaturated fatty acids decrease expression of promoters with sterol regulatory elements by decreasing levels of mature sterol regulatory element-binding protein. J. Biol. Chem. 273, 25537-25540.

Xu, J., Nakamura, M. T., Cho, H. P. and Clarke, S. D. (1999). Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J. Biol. Chem. 274, 23577-23583.

Yahagi, N., Shimano, H., Hasty, A. H., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Shionoiri, F., Ohashi, K., Osuga, J.-i. et al. (1999). A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J. Biol. Chem. 274, 35840-35844.

Yamato, S., Shionohara, K., Nakagawa, S., Kubota, A., Inamura, K., Watanabe, G., Hirayama, S., Milia, T. and Ohta, S. (2009). High-performance liquid chromatography determination of ketone bodies in human plasma by precolumn derivatization with p-nitrobenzene diazonium fluoroborate. Anal. Biochem. 384, 145-150.

Yin, W., Carballo-Jane, E., McLaren, D. G., Mendoza, V. H., Gagen, K., Geoghagen, N. S., McNamara, L. A., Gorski, J. N., Eiermann, G. J., Petrov, A. et al. (2012). Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J. Lipid Res. 53, 51-65.

Yoshikawa, T., Shimano, H., Yahagi, N., Ide, T., Amemiya-Kudo, M., Matsuzaka, T., Nakakuki, M., Tomita, S., Okazaki, H., Tamura, Y. et al. (2002). Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J. Biol. Chem. 277, 1705-1711.

Zahler, W. L., Barden, R. E. and Cleland, W. W. (1968). Some physical properties of palmitoyl-coenzyme A micelles. Biochim. Biophys. Acta 164, 1-11.